Torben Fog – A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research
SAGE Journals » Multiple Sclerosis Journal
by Per Soelberg Sørensen, Stephan Bramow, Melinda Magyari, Lene Werdelin, Nils Koch-Henriksen, Patrick Vermersch, Finn Sellebjerg
3d ago
Multiple Sclerosis Journal, Ahead of Print. Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calcu ..read more
Visit website
Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort
SAGE Journals » Multiple Sclerosis Journal
by Elisabeth Maillart, Stefania Redolfi, Céline Louapre, Marion Houot, Emeline Chaugne, Pierantonio Laveneziana, Aurelian Ungureanu, Bruno Stankoff, Isabelle Arnulf, Caroline Papeix, Benedetta Bodini, Thomas Similowski, Catherine Lubetzki, Capucine Morélot-Panzini
5d ago
Multiple Sclerosis Journal, Ahead of Print. Background:Respiratory disorders remain incompletely described in multiple sclerosis (MS), even though they are a frequent cause of death.Methods:The objective was to describe respiratory disorders in MS patients with Expanded Disability Status Score (EDSS) ⩾ 6.5. Diaphragm dysfunction was defined by at least two of the seven criteria: clinical signs, inspiratory recruitment of neck muscles during wakefulness, reduced upright vital capacity (VC) < 80%, upright-to-supine VC ⩾ 15% of upright VC, decrease in Maximal Inspiratory Pressure < 60%, pha ..read more
Visit website
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry
SAGE Journals » Multiple Sclerosis Journal
by Maria Pia Campagna, Eva Kubala Havrdova, Dana Horakova, Guillermo Izquierdo, Fuencisla Matesanz, Sara Eichau, Jeannette Lechner-Scott, Bruce V Taylor, Maria-Isabel García-Sanchéz, Antonio Alcina, Anneke van der Walt, Helmut Butzkueven, Vilija G Jokubaitis
5d ago
Multiple Sclerosis Journal, Ahead of Print. Background:The International Multiple Sclerosis Genetics Consortium and MultipleMS Consortium recently reported a genetic variant associated with multiple sclerosis (MS) severity. However, it remains unclear if these variants remain associated with more robust, longitudinal measures of disease severity.Methods:We examined the top variant, rs10191329, from Harroud et al.’s study in 1813 relapse-onset MS patients from the MSBase Registry to assess association with longitudinal disease severity.Results:Our analysis revealed no significant association be ..read more
Visit website
Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
SAGE Journals » Multiple Sclerosis Journal
by Henrik Hjalgrim, Klaus Rostgaard
5d ago
Multiple Sclerosis Journal, Ahead of Print ..read more
Visit website
Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003–2023
SAGE Journals » Multiple Sclerosis Journal
by Raphael Goldacre
5d ago
Multiple Sclerosis Journal, Ahead of Print. Background:Epstein–Barr virus (EBV) is thought to be a necessary causative agent in the development of multiple sclerosis (MS). Infectious mononucleosis (IM), which occurs up to 70% of adolescents and young adults with primary EBV infection, appears to be a further risk factor but few studies have been highly powered enough to explore this association by time since IM diagnosis.Objective:The objective was to quantify the risk of MS in individuals with IM compared with the general population, with particular focus on time since IM diagnosis.Methods:In ..read more
Visit website
Facial pain in MS: When to think of trigeminal autonomic cephalalgia
SAGE Journals » Multiple Sclerosis Journal
by Sanjay Cheema, Manjit Matharu
1w ago
Multiple Sclerosis Journal, Ahead of Print ..read more
Visit website
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study
SAGE Journals » Multiple Sclerosis Journal
by Fabrizia Mealli, Alessandra Mattei, Alice Mariottini, Luca Massacesi
2w ago
Multiple Sclerosis Journal, Ahead of Print. To quantify the probability that monthly intravenous (IV) and subcutaneous (SC) natalizumab (NTZ) had similar efficacy in relapsing-remitting multiple sclerosis (RRMS), non-inferiority of efficacy of NTZ-SC versus NTZ-IV on combined MRI unique active lesions number (CUAL) was explored re-analysing the REFINE data set. Non-inferiority margins were selected equal to 25%/33%/50% fractions of the effect size of NTZ-IV versus placebo observed in the AFFIRM study. Ninety-nine RRMS were included. NTZ-SC resulted not inferior to NTZ-IV on CUAL for all margin ..read more
Visit website
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study
SAGE Journals » Multiple Sclerosis Journal
by M Johnsson, YT Stenberg, HH Farman, K Blennow, H Zetterberg, C Malmeström, S Sandgren, I Rosenstein, J Lycke, M Axelsson, L Novakova
2w ago
Multiple Sclerosis Journal, Ahead of Print. Background:Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS). However, the diagnostic properties of sNfL for monitoring disease activity in individual patients warrant further investigations.Method:Patients with suspected relapse and/or contrast-enhancing lesions (CELs) were consecutively included and performed magnetic resonance imaging (MRI) of the brain at baseline and weeks 28 and 48. Serum was obtained at baseline and 2, 4, 8, 16, 24, an ..read more
Visit website
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial
SAGE Journals » Multiple Sclerosis Journal
by Kunio Nakamura, Zhaonan Sun, Claire Hara-Cleaver, Karthik Bodhinathan, Robin L Avila
2w ago
Multiple Sclerosis Journal, Ahead of Print. Background:Loss of brain gray matter fractional volume predicts multiple sclerosis (MS) progression and is associated with worsening physical and cognitive symptoms. Within deep gray matter, thalamic damage is evident in early stages of MS and correlates with physical and cognitive impairment. Natalizumab is a highly effective treatment that reduces disease progression and the number of inflammatory lesions in patients with relapsing-remitting MS (RRMS).Objective:To evaluate the effect of natalizumab on gray matter and thalamic atrophy.Methods:A comb ..read more
Visit website
Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review
SAGE Journals » Multiple Sclerosis Journal
by Rainer Ehling, Barbara Seebacher, Christian Brenneis
2w ago
Multiple Sclerosis Journal, Ahead of Print ..read more
Visit website

Follow SAGE Journals » Multiple Sclerosis Journal on FeedSpot

Continue with Google
Continue with Apple
OR